Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in the Treatment of Medullary Thyroid Cancer

Abstract

The aim of the work was to systematically evaluate the efficacy and safety of Vandetanib in the treatment of advanced medullary thyroid carcinoma (MTC). MeSH entries to search for randomized controlled trials and clinical research literature on the application of Vandetanib in the treatment of medullary thyroid cancer from PubMed, Chinese national knowledge infrastructure (CNKI), and Web of Science databases since their establishment until March 2023 were used. In terms of efficacy, the analysis results showed that Vandetanib had a significantly higher objective response rate compared to the control group using placebo (OR=2.13, 95% CI: 1.38, 3.29). In terms of side effects, Vandetanib significantly increases the incidence of hypertension, rash, and diarrhea, and has statistical significance (p+<+0.05). Vandetanib has a better therapeutic effect on MTC, but it also increases the incidence of hypertension, rash, and diarrhea. Attention should be paid to the relief of side effects when using it.

Keywords

medullary thyroid carcinoma - Vandetanib - objective response rate - side effects - meta-analysis

Publication History

Received: 27 October 2023

Accepted after revision: 06 December 2023

Article published online:
26 January 2024

• References

• 1 Kim M, Kim BH. Current guidelines for management of medullary thyroid Carcinoma. Endocrinol Metab (Seoul) 2021; 36: 514-524
• 2 Baloch ZW, Asa SL, Barletta JA. et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 2022; 33: 27-63
• 3 Jayasinghe R, Basnayake O, Jayarajah U. et al. Management of medullary carcinoma of the thyroid: a review. J Int Med Res 2022; 50: 3000605221110698
• 4 Ceolin L, Duval M, Benini AF. et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer 2019; 26: R499-R518
• 5 Leimbach RD, Hoang TD, Shakir MKM. Diagnostic challenges of medullary thyroid carcinoma. Oncology 2021; 99: 422-432
• 6 Filetti S, Durante C, Hartl D. et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2019; 30: 1856-1883
• 7 De Luca A, D’Alessio A, Maiello MR. et al. Vandetanib as a potential treatment for breast cancer. Expert Opin Investig Drugs 2014; 23: 1295-1303
• 8 Morabito A, Piccirillo MC, Costanzo R. et al. Vandetanib: an overview of its clinical development in NSCLC and other tumors. Drugs Today (Barc). 2010. 46. 683-698
• 9 Wells SA, Robinson BG, Gagel RF. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141
• 10 Wang SX, Zhang XW, Wang XX. et al. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase III study]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2019; 54: 439-444
• 11 Uchino K, Komoda M, Tomomatsu J. et al. Safety and tolerability of vandetanib in Japanese patients with medullary thyroid cancer: a phase I/Ii open-label study. Endocr Pract 2017; 23: 149-156
• 12 Robinson BG, Paz-Ares L, Krebs A. et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2664-2671
• 13 Wells SA, Gosnell JE, Gagel RF. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28: 767-772
• 14 Zhang L, Li S, Zhang Y. et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther 2011; 33: 315-327
• 15 Hu MI, Elisei R, Dedecjus M. et al. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer 2019; 26: 241-250
• 16 Fallahi P, Ferrari SM, Galdiero MR. et al. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol 2022; 79: 180-196
• 17 Tsang VH, Robinson BG, Learoyd DL. The safety of vandetanib for the treatment of thyroid cancer. Expert Opin Drug Saf 2016; 15: 1107-1113
• 18 Leboulleux S, Bastholt L, Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13: 897-905
• 19 Chougnet CN, Borget I, Leboulleux S. et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 2015; 25: 386-391
• 20 Weber MA, Schiffrin EL, White WB. et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3-15